These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35220231)

  • 1. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
    Saller JJ; Haider M; Al-Diffalha S; Coppola D
    Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors.
    Kerr SE; Schnabel CA; Sullivan PS; Zhang Y; Huang VJ; Erlander MG; Brachtel EF; Dry SM
    Mod Pathol; 2014 Jan; 27(1):44-54. PubMed ID: 23846576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
    Bellizzi AM
    Adv Anat Pathol; 2013 Sep; 20(5):285-314. PubMed ID: 23939147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer.
    Kulkarni A; Pillai R; Ezekiel AM; Henner WD; Handorf CR
    Diagn Pathol; 2012 Aug; 7():110. PubMed ID: 22909314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.
    Handorf CR; Kulkarni A; Grenert JP; Weiss LM; Rogers WM; Kim OS; Monzon FA; Halks-Miller M; Anderson GG; Walker MG; Pillai R; Henner WD
    Am J Surg Pathol; 2013 Jul; 37(7):1067-75. PubMed ID: 23648464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single institutional experience on primary neuroendocrine neoplasms of the kidney: a rare distinct entity.
    Amin M; Trikalinos N; Chatterjee D
    Hum Pathol; 2021 Aug; 114():36-43. PubMed ID: 33891968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification].
    Morawietz L; Floore A; Stork-Sloots L; Folprecht G; Buettner R; Rieger A; Dietel M; Huebner G
    Pathologe; 2009 Dec; 30 Suppl 2():168-72. PubMed ID: 19756615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.
    Maxwell JE; Sherman SK; Stashek KM; O'Dorisio TM; Bellizzi AM; Howe JR
    Surgery; 2014 Dec; 156(6):1359-65; discussion 1365-6. PubMed ID: 25456909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases.
    Posorski N; Kaemmerer D; Ernst G; Grabowski P; Hoersch D; Hommann M; von Eggeling F
    Clin Exp Metastasis; 2011 Oct; 28(7):637-47. PubMed ID: 21681495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary.
    Chauhan A; Farooqui Z; Silva SR; Murray A; Hodges KB; Yu Q; Myint ZW; Raajesekar AK; Weiss H; Arnold S; Evers BM; Anthony L
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):113-116. PubMed ID: 30678389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary.
    Fuentes Bayne HE; Kasi PM; Ma L; Hart LL; Wong J; Spigel DR; Schnabel CA; Reeves JA; Halfdanarson TR; Treuner K; Greco FA
    JCO Precis Oncol; 2024 Sep; 8():e2400191. PubMed ID: 39231374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.
    Modlin IM; Drozdov I; Kidd M
    PLoS One; 2013; 8(5):e63364. PubMed ID: 23691035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
    Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
    Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy?
    Koo J; Dhall D
    Semin Diagn Pathol; 2015 Nov; 32(6):456-68. PubMed ID: 26573790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of miR-96 and miR-133a Expression in Gastrointestinal Neuroendocrine Neoplasms.
    Mandal R; Hardin H; Baus R; Rehrauer W; Lloyd RV
    Endocr Pathol; 2017 Dec; 28(4):345-350. PubMed ID: 29032398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Yin F; Wu ZH; Lai JP
    World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.